Current views on the etiopothogenesis of goiter in children;Współczesne pogla̧dy no etiopatogenezȩ wola u dzieci

Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego

Volumn 12, Issue 1, 2006, Pages 35-43

  Brzozowska, Małgorzata ^a   Krȩtowski, Adam ^a,b  

^a AM ^*  (Poland)

^b Klinika Endokrynologii   (Poland)

Author keywords

Goiter; Hyperplasia hyperthrophy

Indexed keywords

AUTOIMMUNE DISEASE; CELL HYPERPLASIA; CHILD; ENDEMIC DISEASE; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HEREDITY; HUMAN; HYPERPLASIA; HYPERTROPHY; IODINE DEFICIENCY; PATHOGENESIS; REVIEW; THYROID FOLLICLE CELL; THYROID GLAND; THYROID HORMONE SYNTHESIS; ENDEMIC GOITER; ENVIRONMENTAL EXPOSURE; PATHOLOGY; PATHOPHYSIOLOGY;

IODINE;

CHILD; ENVIRONMENTAL EXPOSURE; GOITER; GOITER, ENDEMIC; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; HYPERPLASIA; IODINE; THYROID GLAND;

EID: 33645996741     PISSN: 1234625X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Peterson S., Sanga A., Eklof H. i wsp.: Classification of thyroid size by palpation and ultrasonography in field surveys. Lancet, 2000, 355, 106.
2. Gembicki M., Ruchata M., Bartkowiak M. i wsp.: The results of epidemiological studies concerning iodine deficiency and goiter in Poznan Region (Poznan coordinating center). Endokrynol. Pol., 1993, 44, 317.
3. Kinalska I., Borawski J., Krȩtowski A. i wsp.: Iodine deficiency disorders in the north-eastern region of Poland (Białystok coordinating center). Endokrynol. Pol., 1993, 44, 297.
4. Kinalska I., Zarzycki W., Zonenberg A. i wsp.: Epidemiologia chorób tarczycy w Polsce Północno-Wschodniej. Pol. Endokrynol., 1995, 46, supl. do nr. 1, 63.
5. Rybakowa M., Tylek-Lemańska B., Ratajczak R., Sołtysik-Wilk E.: Iodine defitiency in children from Tarnobrzeg district. Endokrynol. Pol., 1998, 49, supl. 1 do nr. 3, 115.
6. Grüters A.: Treatment of Graves' disease in children and adolescents. Norm Res., 1998, 49, 255-257.
7. Hunter I., Greene S.A., Macdonald T.M., Morrie A.D.: Prevalence and aetiology of hypothyroidism in the young. Arch. Dis. Child., 2000, 83, 207.
8. Jaruratanasirikul S., Leethanaporn K., Khuntigij P., Sriplung H.: The clinical course of Hashimoto's thymiditis in children and adolescents: 6 years longitudinal follow up. J. Clin. Endocrinol. Metab., 2001, 14, 177.
9. 2-generating activity. J. Clin. Endocrinol. Metab., 2001, 86, 4863.
10. Gonzalez Trevino O., Karamanoglu Arseven O., Ceballos C.J. i wsp.: Clinical and molecular analysis of the three Mexican familes with Penderd's syndrome. Eur. J. Endocrinol, 2001, 144, 585.
11. Royaux E.I., Suzuki K., Mori A. i wsp.: Pendrin, the protein encoding the syndrome gene (PDS), is an aplical porter of iodide in the thyroid and is regulated by thyreoglobulin in cells. Endocrinol., 2000, 141, 839.
12. Nikiforov Y., Gnepp D.R., Fagin J.A.: Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J. Clin. Endocrinol. Metab, 1996, 81, 9.
13. Pacini F., Vorontsova T., Demidchik E.P. i wsp.: Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with natural occurring thyroid carcinoma in Italy and France. J. Clin. Endocrinol. Metab., 1997, 82, 3563
14. Zhao I., Chen Z., Maberly G.: Iodine-rich drinking water of natural origin in China. Lancet, 1998, 352, 207.
15. Zhao J., Wang P., Shang L. i wsp.: Endemic goiter associated with high iodine intake. Am. J. Public Health, 2000, 90, 1633.
16. Doufas A.G., Mastorakos G., Chatiioannou S. i wsp.: The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur. J. Endocrinol., 1999, 140, 505.
17. Loviselli A., Velluzzi F., Mossa P., Cambosu M.A. i wsp.: The Sardinian autoimmunity study: 3. Studies on circulating anthityroid antibodies in Sardinian schoolchildren: relationship to goiter prevalence and thyroid function. Thyroid, 2001, 11, 849.
18. Marwaha R.K., Tandon N., Karak A.K. i wsp.: Hashimoto's thyroiditis: countryside screening of goitrous healthy young girls in postiodization phase in India. J. Clin. Endocrinol. Metab., 2000, 85, 3798.
19. Kraiem Z., Newfield R.S.: Graves' disease in childhood. J. Pediatric. Endocrinol. Metab., 2001, 14, 229.
20. Paschke R., Eck T., Herfurth J., Usadel K.H.: Stimulation of proliferation and inhibition of function of xenotransplanted human thyroid tissue by epidermal growth factor. J. Endocrinol. Invest., 1995, 18, 359-363.
21. Constans J., Ribouchon M.T., Gouaillard C. i wsp.: A new polymorphism of thyroxin-binding globulin in three African groups (Mali) with endemic nodular goitre. Hum. Genet., 1992, 89, 199.
22. Taylor J.P., Metcalfe R.A., Watson P.F. i wsp.: Mutations of the PDS gene encoding Pendrin are associated with protein mislocalization and loss of iodide efflux: implications for thyroid dysfunction in Pendred syndrome. J. Clin. Endocrinol. Metab., 2002, 87, 1778.
23. Kappa P.: Pendred's syndrome: identification of the genetic defect a century after its recognition. Thyroid, 1999, 9, 65.
24. Cremers W.R., Bolder C., Admiraal R.J. i wsp.: Progressive sensorineural hearing loss and awidened vestibular aqueduct in Pendred syndrome. Arch. Otolaryngol. Head Neck Surg., 1998, 124, 501
25. Krude H., Biedermann H., Schnabel D., Anbrugger P.: Molecular pathogenesis of neonatal hypothyroidism. Norm Res., 2000, 53, 12.
26. Bakker B., Bikker H., Vulsma T. i wsp.: Two decades of screening for congenital hypothyroidism in the Netherlands: TPO gene mutations in total iodide organification defects (an update). J. Clin. Endocrinol. Metab., 2000, 85, 3708.
27. Refetoff S.: Resistance to thyrotropin. J. Endocrinol. Invest., 2003, 26, 770.
28. Neumann S., Wiligerodt H., Ackermann F. i wsp.: Linkage of familial euthyroid goiter to the multinodullar goiter 1 locus and exclusion of the candidate genes thyreoglobulin, thyreopemxidase, and Na+/J-symporter. J. Clin. Endocrinol. Metab., 1999, 84, 3750.
29. Spitzweg C., Heufelder A., Morris J.: Thyroid iodine transport. Thyroid, 2000, 10, 321.
30. Dremier S., Coulonval K., Perpete S. i wsp.: The role of cyclic AMP and its effect on protein kinase A in the mitogenic action of thyrotropin on the thyroid cell. Ann. N.Y. Acad. Sci., 2002, 968, 106.
31. Medina D.L., Santisteban P.: Thyreopropin- dependent proliferation of in vitro rat thyroid cell systems. Eur. J. Endocrinol., 2000, 143, 161.
32. Pomerance M., Abdullah H.B., Kamerji S. i wsp.: Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade. J. Biol. Chem., 2000, 25, 40539.
33. Pirson I., Fortemaison N., Jacobs C. i wsp.: The visual display of regulatory information and networks. Trends Cell Biol., 2000, 10, 404.
34. Van Keymeulen A., Bartek J., Dumont J.E., Roger P.P.: Cyclin D3 accumulation and activity integrate and rank the comitogenic pathways of thyrotropin and insulin in thyrocytes in primary culture. Oncogene, 1999, 18, 7351.
35. Kogai T., Endo T., Saito T. i wsp.: Regulation by thyroid-stimulating hormone of sodium/ iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinol., 1997, 138, 2227.
36. Pekary A.E., Hersham J.M.: Tumor necrosis factor, ceramide transforming growth factor-β1, and aging reduce Na+/J- symporter messenger ribonuclein acid levels in FRTL-5 cells. Endocrinol. 1998, 139, 703.
37. +/J- symporter in caltured human thyroid cells exsposed to thyrotropin and in Graves tissue. J. Clin. Endocrinol. Metab., 1997, 82, 3331.
38. Larsen P.R., Davies T.F., Schlumberger M.J., Hay I.D.: Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. [w:] Larsen P.R., Kronenberg H., Melmed S. i wsp.: Williams textbook of endocrinology, wyd. 10. Elsevier, Philadelphia, 2003, 331.
39. Baserga R., Sell C., Porcu P., Rubini M.: The role of the IGF-1 receptor in the growth and transformation of mammalian cells. Cell Prolif., 1994, 27, 63.
40. Cass L.A., Summers S.A., Prendergast G.V. i wsp.: Protein kinase A dependent and independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol., 1999, 19, 5882.
41. Dremier S., Pohl V., Poteet-Smith C. i wsp.: Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP dependent DNA synthesis and thyreoglobulin expression in dog thyroid cells. Mol. Cell Biol., 1997, 17, 6717.
42. Krantz D.E., Waites C., Oorschot V. i wsp.: A phosphorylation site regulates sorting of the vesicular acetylocholine transporter to dense core vesicles. J. Cell. Biol., 2000, 149, 379-396.
43. Tsygankova O.M., Kupperman E., Wen W., Meinkoth J.I.: Cyclic AMP activates. Res. Oncogene., 2000, 19, 3609.
44. Tsygankova O.M., Saavedra A., Rebhun J.F., Quilliam L.A.: Meinkoth JI. Coordinated regulation of Rap 1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol. Cell Biol., 2001, 21, 1921.
45. Deleu S., Pirson I., Coulonval K. i wsp.: IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Moll. Cell. Endocrinol., 1999, 149, 41.
46. Nedachi T., Akahori M., Ariga M. i wsp.: Tyrosine kinase and phosphatidylinositol 3-kinase activation are required for cyclic adenosine 3′5′-monophosphate-dependent potentiation of deoxyribonucleic acid synthesis induced by insulin-like growth factor-1 in FRTL-5 cells. Endocrinol., 2000, 141, 2429.
47. Van Keymeulen A., Dumont J.E., Roger P.P.: TSH induces insulin receptors that mediate insulin co stimulation of growth in normal human thyroid cells. Biochem. Biophys. Res. Commun., 2000, 279, 202.
48. Saji M., Akamizu T., Sanchez M. i wsp.: Regulation of TSH receptor gene expression in rat FRTL-5 thyroid cells. Endocrinol., 1992, 130, 520.
49. Köhrle J.: The trace element selenium and the thyroid gland. Biochemie, 1999, 81, 527.
50. Takada K., Amino N., Tada H., Miyai K.: Relationships between proliferation and cell cycle dependent Ca+2 influx induced by a combination of thyreotropin and IGF-1 in rat thyroid cells. J. Clin. Invest., 1990, 86, 1548.
51. Takasu N., Takasu M., Komiya I. i wsp.: IGF-1 stimulates inositolphosphate accumulation, a rise in cytoplasmic free calcium, and proliferation in culture porcine thyroid cells. J. Biol. Chem., 1989, 264, 18485.
52. Garcia B., Santiseban P.: PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. Mol. Endocrinol., 2002, 16, 342-352.
53. Napolitano G., Montani V., Giuliani C. i wsp.: TGF-beta1 down-regulation of MHC class I in thyreocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription factors. Mol. Endocrinol., 2000, 14, 486.
54. Mincione G., Esposito D.L., Di Marcantonio M.D. i wsp.: TGF-beta1 odulation of IGF-I signaling pathway in rat thyroid epithelial cells. Exp. Cell Res., 2003, 287, 411.
55. Duh Q.Y., Siperstein A.E., Miller R.A. i wsp.: Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. World J. Surg., 1990, 14, 410.
56. Westermark K., Karlsson A., Westermark B.: Thyreotropin modulates EGF receptor function in porcine thyroid follicle cells. Mol. Cell. Endocrinol., 1985, 40, 17.
57. Emoto N., Isozaki O., Arai M. i wsp.: Identification and characterization of basic fibroblast growth factors in parcine thyroids. Endocrinol., 1991, 128, 58.
58. Cocks H.C., Ramsdern J.D., Davies E.L. i wsp.: TSH increases angiogenic growth factor expression in FRTL-5 cells. Endocrinol. J., 2000, 47, supl. 42 (Abstract).
59. Caturegli P., Hejazi M., Suzuki K. i wsp.: Hypotyroidism in transgenic mice expressing INF-g in the thyroid. Proc. Natl. Acad. Sci. USA., 2000, 97, 1719.
60. Mori K., Stone S., Khaodhiar L. i wsp.: Induction of transcription factor interferon-g and tumor necrosis factor-a in FRTL-5 cells. J. Cell. Biochem., 1999, 74, 211.
61. Pekary A.E., Levin S.R., Johnson D.C. i wsp.: Tumor necrosis factor-a (TNF-a) and transforming growth factor-β1 inhibit the expression and activity of NA+/K+ ATPase in FRTL-5 rat thyroid cells. J. Interferon. Cytokine Res., 1997, 185.
62. Akamizu T.: Antithyrotropin receptor antibody: an update. Thyroid, 2001, 12, 1123.
63. Davies T., Marians R., Latif R.: The TSH receptor reveals itself. J. Clin. Invest., 2002, 110, 161.
64. Gardziejczyk M., Urban M., Bossowski A., Kitszel A.: Przeciwciała przeciwtarczycowe w wolu endemicznym u dzieci. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw, 1997, 3, 83.
65. Vitti P., Chiovato L., Tonacchera M. i wsp.: Failure to detect thyroid growth promoting activity in immunoglobulin G of patients with endemic goiter. J. Clin. Endocrinol. Metab., 1994, 78, 1020.
66. Davies R., Lawory J., Bhatia V., Weetman A.P.: Growth stimulating antibodies in endemic goitre: a reappraisal. Clin. Endocrinol. (Oxf.), 1995, 43, 189.
67. Smyth P.P.A., Darke C., Parkes A.B. i wsp.: Assessment of goiter in an area of endemic iodine deficiency. Thyroid, 1999, 9, 895.
68. Premawardhana L.D.K.E., Parkes A.B., Smyth P.P.A. i wsp.: Increased prevalence of thyroglobuin antibodies in Sri Lankan schoolgirls - is iodine the cause? Eur. J. Endocrinol., 2000, 143, 185.
69. Segni M., Leonardi E., Mazzoncini B. i wsp.: Special features of Graves' disease in early childood. Thyroid, 1999, 9, 871.
70. Brix T.H., Hegedüs L.: Genetic and environmental factors in the etiology of simple goitre. Ann Med., 2000, 32, 153.
71. Brix T.H., Kyvik K.O., Hegedüs L.: Major role of genes in the etiology of simple goiter in females: a population based twin study. J. Clin. Endocrinol. Metab., 1999, 84, 3071.
72. McKay J.D., Wiliamson J., Lesueur F. i wsp.: At least three genes account for familial papillary thyroid carcinoma: TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family. Eur. J. Endocrinol., 1999, 141, 122.
73. Neumann S., Bayer Y., Reske A. i wsp.: Further indications for genetic heterogeneity of euthyroid familial goiter. J. Mol. Med., 2003, 81, 736.
74. Bignell G.R., Canzian F., Shayeghi M. i wsp.: Familial nontoxic multinodullar thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am. J. Hum. Genet., 1997, 61, 1123.
75. Lewiński A., Karbownik M., Tomaszewski W. i wsp.: Incidence of goitre and urinary iodide concentration in schoolchildren in the town Opoczno (the Piotrków Trybunalski Voivodship). Endokrynol. Pol., 1998, 49, supl. 1 do nr 3, 101.
76. Erdogan G., Erdogan M.F., Emral R. i wsp.: Iodine status and goiter prevalence in Turkey before mandatory iodization. J. Endocrinol. Invest., 2002, 25, 224.
77. Smith T.J., Sciaky D., Phipps R.P., Jennings T.A.: CD4 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid, 1999, 9, 749.
78. WHO, ICCIDD: Recommended normative values for thyroid volume in children aged 6-15 years. Bull. World Health Organ, 1997, 75, 95.
79. Wolff J., Chaikoff I.L.: Plama inorganic iodide as homeostatic regulator of thyroid function. J. Biol. Chem., 1948, 174, 555.
80. Eng P.H.K., Cardona G.R., Fang S.L. i wsp.: Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonuclein acid and protein. Endocrinology, 1999, 140, 3404-3410.
81. Kahaly G.J., Dienes H.P., Beyer J., Hommel G.: Iodide induces thyroid autoimmunity in patients with endemic goitre: randomised, double blind placebo controlled trial. Eur. J. Endocrinol., 1998, 139, 290.
82. Blumberg B., Sabbagh W., Juguilon H. i wsp.: SRX, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev., 1998, 12, 3195.
83. Beard J.L., Borel MJ, Derr J.: Impaired thermoregulation and thyroid function in iron-deficiency anemia. Am. J. Clin. Nutr., 1990, 52, 813.
84. Beard J.L., Brigham D.E., Kelley S.K., Green M.H.: Plasma thyroid hormone kinetics are altered
85. Hess S.Y., Zimmerman M.B., Arnold B.M., Langhaus W, Hurrel R.F.: Iron deficiency anemia lowers thyreoperoxidase activity in rats. J. Nutr., 2002, 132, 1951-1955.
86. Zimmermann M.B., Köhrle J.: The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid, 2002, 12,: 867-878.
87. Zimmermann M., Adou P., Torresani T. i wsp.: Persistence of goiter despite oral iodine suplementation in goitrous children with iron deficiency anemia in Côte d'Ivoire. Am. J. Clin. Nutr., 2000, 71, 88.
88. Zimmermann M., Adou P., Torresani T. i wsp.: Iron supplementation in goitrous, iron deficient children improves their response to oral iodized oil. Eur. J. Endocrinol., 2000, 142, 217.
89. Berry M., Banu L., Larsen P.: Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature, 1991, 349, 438.
90. Erdogan M.F., Erdogan G., Sav H. i wsp.: Endemic goiter, thiocyanate overload, and selenium status in school-age children. Biol. Trace Elem. Res., 2001, 79, 121.
91. Salvatore D., Bartha T., Harney J.W., Larsen P.R.: Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinol., 1996, 137, 3308.
92. Salvatore D., Low S.C., Berry M. i wsp.: Type 3 iodothyronine deiodinase: cloning in vitro expression and functional analysis of the placental selenoprotein. J. Clin. Invest., 1995, 96, 431.
93. Duffield A., Thomson C.D., Hill K.E., William S.: An estimation of selenium requirements for New Zealanders. Am. J. Clin, 1999, 70, 896.
94. Neve J.: Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. J. Trace Elem. Med. Biol., 1995, 9, 65.
95. Giray B., Filiz H.: Oxidative DNA base damage, antioxidant enzyme activities and selenium status in highly iodine-deficient goitrous children. Free Radical Res., 2002, 36, 55-62.
96. Giary B., Hincal F., Tezie T. i wsp.: Status of selenium and antioxidant enzymes of goitrous children is lower than healthy controls and nongoitrous children with high iodine deficiency. Biol. Trace Elem. Res., 2001, 82, 35.
97. Untoro J., Ruz M., Gross R.: Low environmental selenium availability as an additional determinant for goiter in East Java, Indonesia? Biol. Trace Elem. Res., 1999, 70, 127.
98. Zagrodzki P., Szmigiel H., Ratajczak R. i wsp.: The role of selenium in iodine metabolism in children with goiter. Environ. Health Perspect., 2000, 108, 67.
99. Zagrodzki P.: Selenium status and the thyroid function. Endokrynol. Pol., 2001, 52, 573.
100. Puzzulli A., Ranjbar A.: Selenium deficiency and hypothyroidism: a new etiology in the differential diagnosis of hypothyroidism in children. Biol. Trace Elem. Res., 2000, 77, 199.
101. Ruz M., Codoceo J., Galgani J. i wsp.: Single and multiple selenium-zinc-iodine deficiencies affect rat thyroid metabolism and ultrastucture. J. Nutr., 1999, 129, 174.
102. Kralik A., Kirchgessner M., Eder K.: Concentrations of thyroid hormones in serum and activity of hepatic 5′ monodeiodinase in copper deficient rats. Z. Ernahrungswiss., 1996, 35, 288.
103. Boyages S.C.: Clinical review of iodine deficiency disorders. J. Clin. Endocrinol. Metab., 1993, 77, 587.
104. Doerge D.R., Sheehan D.M.: Goitrogenic and estrogenic activity of soy isoflavones. Environ. Health Perspect., 2002, 110, supl. 3, 349.
105. Elnour A., Hambbraecus L., Eltom M. i wsp.: Endemic goiter with iodine sufficiency: a possible role for the consumption of pear millet in the etiology of endemic goiter. Am. J. Clin. Natur., 2000, 71, 59.
106. Bournaud C., Orgiazzi J.J.: Iodine excess and thyroid autoimmunity. J. Endocrinol. Invest., 2003, 26, supl. do nr 2, 49.
107. Fan A.M., Steinberg V.E.: Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Regul. Toxicol. Pharmacol., 1996, 23, 1 Pt 1, 35-43.
108. Gatseva P., Vladeva S., Pavlov K.: Incidence of goiter among children in a village with nitrate contamination of drinking water. Folia Med., 1998, 40, 19.
109. Gatseva P., Lazarova A., Maximova S., Pavlova K.: Experimental data on the effect of nitrates entering the organism with the drinking water. Folia Med., 1996, 38, 75.
110. Jooste PL, Weight MJ, Lombard CJ: Short term effectiveness of mandatory iodization of table salt, at an elevated iodine concentration, on the iodine and goiter status of schoolchildren with endemic goiter. Am J Clin Nutr., 2000, 71, 75.
111. Januszko T., Suszczyńska-Faleck Z., Karczewski J. i wsp.: Próba kwalifikacji województwa białostockiego jako terenu endemicznego wola. Rocz. AM Białystok., 1978, 23, 171.
112. Knudsen N., Bülow I., Jorgensen T. i wsp.: Goitre prevalence and thyroid abnormalities at ultrasonography. A comparative epidemiological study in two regions with slightly different iodine status. Clin. Endocrinol. (Oxf.), 2000, 53, 479.
113. Knudsen N., Bülow I., Laurberg P. i wsp.: Association of tobacco smoking with goiter in a low iodine intake area. Arch. Intern. Med., 2002, 162, 439.
114. Zonenberg A., Telejko B., Zarzycki W. i wsp.: Badania epidemiologiczne tarczycy na terenie gminy Sejny. Endokrynol. Pol., 1992, 43, 377.
115. Corapcioglu D., Tonyukuk V., Kiyan M.i wsp.: Relationship between thyroid autoimmunity and Yersinia. Enterocolitica antybodies. Thyroid, 2002, 12, 613.
116. Strieder T.G., Wenzel B.E., Prummel M.F. i wsp.: Increased prevalence of antibodies to enteropathogenic Yersinia enterocolitica virulence proteins in relatives of patients with autoimmune thyroid disease. Clin. Exp. Immunol., 2003, 132, 278.
117. Marcinkowska M., Gesing A., Lewiriski A.: Lekia czynność tarczycy. Endokrynol. Pol., 1997, 48, supl. 2 do nr. 2, 121.
118. Lazarus J.H.: Effects of lithium on the thyroid gland. [w:] Pharmacotherapeutics of the thyroid gland. A.P. Weetman, A. Grossman (red.), Springer, Berlin, 1996, 207.
119. Ramsden J.D.: Angiogenesis in the thyroid gland. J. Endocrinol., 2000, 166, 475.